Fig 1.
A schematic description of patient selection and follow-up.
Of a possible 2,756 patients, 1,321 were eligible for inclusion in the study. 1,282 were eligible for inclusion in the final analysis for immunological treatment failure.
Table 1.
Characteristics of patients on anti-retroviral therapy, (N = 1,321).
Table 2.
Final follow-up status by demographic and baseline characteristics of study patients on anti-retroviral therapy (N = 1,321).
Fig 2.
Pattern of CD4 cell count monitoring by follow-up time (N = 1,321).
The actual number of CD4 cell count tests performed is seen to decline over time even taking into account the progressively lesser number of patients in care as the length of follow-up increased.
Table 3.
Determination of timely follow-up CD4 testing by follow-up period in months among patients on anti-retroviral therapy (N = 1,321).
Table 4.
Determination of timely follow-up CD4 cell count testing by demographic and baseline treatment variables among patients on anti-retroviral therapy (N = 1,321).
Fig 3.
Box plot for magnitude of baseline and follow-up CD4 cell count among cohort of patients on anti-retroviral therapy by follow-up month (N = 1,321).
The group level CD4 cell count as measured by median CD4 cell count at a particular follow-up time is seen to increase at first and plateau then after.
Table 5.
Magnitude of follow-up CD4 cell count by demographic and baseline treatment variables among patients on anti-retroviral therapy (N = 1,321).
Table 6.
Immunological treatment failure among patients on anti-retroviral therapy (N = 1,321).
Table 7.
Diagnostic criteria for initial immunological failure among study patients on anti-retroviral therapy in (n = 226).
Table 8.
Follow-up immunological evaluation and final immunological status of patients with immunological failure (n = 226).
Table 9.
Frequency distribution of patients on second line treatment among those with confirmed immunological failure (n = 93).
Fig 4.
Kaplan-Meier survival functions for survival free of immunological treatment failure (n = 1,282).
The even free survival probability, the event being free of immunological treatment failure, decreased steadily.
Table 10.
Description of follow-up time in years for study patients on anti-retroviral therapy (n = 1,282).
Table 11.
Life table for immunological failure among patients on anti-retroviral therapy (n = 1,282).
Fig 5.
Kaplan-Meier survival functions by WHO Stage (n = 1,282).
Event free survival, the even being free of immunological treatment failure, was higher for patients with WHO stages I or II as compared to those with WHO stage III or IV.
Fig 6.
Kaplan-Meier survival functions by baseline CD4 cell count group (n = 1,282).
Event free survival, the even being free of immunological treatment failure, was lower for patients with baseline CD4 cell count more than 349 as compared to those with other CD4 cell count categories.
Table 12.
Cox proportional hazards regression analysis for predictors of immunological failure among patients on anti-retroviral therapy (n = 1,282).
Table 13.
Immunologic failure risk assessment and management tool.